Toll like receptor modulator compounds

Patent metadata

Field	Value
Publication number	US-10640499-B2
Application number	US-201715692161-A
Country	US
Kind code	B2
Filing date	Aug 31, 2017
Priority date	Sep 2, 2016
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them. The toll-like receptor modulators of the present invention include compounds such as

First claim

What is claimed is:

1. A compound, which is

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 6 , further comprising one or more additional therapeutic agents.

8. The pharmaceutical composition of claim 7 , wherein the one or more additional agents are selected from the group consisting of HBV DNA polymerase inhibitors, toll-like receptor 7 modulators, toll-like receptor 8 modulators, toll-like receptor 7 and 8 modulators, toll-like receptor 3 modulators, interferon alpha ligands, HBsAg inhibitors, compounds targeting HbcAg, cyclophilin inhibitors, HBV therapeutic vaccines, HBV prophylactic vaccines, HBV viral entry inhibitors, Na+-taurocholate cotransporting polypeptide (NTCP) inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA), hepatitis B virus E antigen inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus, thymosin agonists, cytokines, HBV core or capsid protein inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of nucleotide-binding oligomerization domain-containing protein 2 (NOD2), recombinant thymosin alpha-1 and hepatitis B virus replication inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, indoleamine-2,3-dioxygenase (IDO) inhibitors, and combinations thereof.

9. The pharmaceutical composition of claim 7 , wherein the one or more additional therapeutic agents are selected from the group consisting of entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine.

10. The pharmaceutical composition of claim 7 , wherein the one or more additional therapeutic agents are selected from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, pharmacokinetic enhancers, and combinations thereof.

Assignees

• Gilead Sciences Inc

Inventors

• Chin Gregory
• Mackman Richard L
• Mish Michael R
• Zablocki Jeff

Classifications

• C07D487/04

  Ortho-condensed systems · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61P31/22

  for herpes viruses · CPC title